Zuccari Guendalina, Baldassari Sara, Alfei Silvana, Marengo Barbara, Valenti Giulia Elda, Domenicotti Cinzia, Ailuno Giorgia, Villa Carla, Marchitto Leonardo, Caviglioli Gabriele
Department of Pharmacy (DiFAR), University of Genoa, Viale Cembrano 4, 16148 Genova, Italy.
Department of Experimental Medicine-DIMES, University of Genoa, Via Alberti L.B. 2, 16132 Genova, Italy.
Pharmaceuticals (Basel). 2021 Mar 4;14(3):212. doi: 10.3390/ph14030212.
All--retinoic acid (ATRA) represents the first-choice treatment for several skin diseases, including epithelial skin cancer and acne. However, ATRA's cutaneous side effects, like redness and peeling, and its high instability limit its efficacy. To address these drawbacks and to improve ATRA solubilization, we prepared ATRA-loaded micelles (ATRA-TPGSs), by its encapsulation in D-α-tocopheryl-polyethylene-glycol-succinate (TPGS). First, to explore the feasibility of the project, a solubility study based on the equilibrium method was performed; then, six ATRA-TPGS formulations were prepared by the solvent-casting method using different TPGS amounts. ATRA-TPGSs showed small sizes (11-20 nm), low polydispersity, slightly negative zeta potential, and proved good encapsulation efficiency, confirmed by a chemometric-assisted Fourier transform infrared spectroscopy (FTIR) investigation. ATRA-TPGS stability was also investigated to choose the most stable formulation. Using Carbopol 980 as gelling agent, ATRA-TPGS-loaded gels were obtained and analyzed for their rheological profiles. Ex vivo release studies from ATRA-TPGSs were performed by Franz cells, demonstrating a permeation after 24 h of 22 ± 4 µ cm. ATRA-TPGSs showed enhanced cytotoxic effects on melanoma cells, suggesting that these formulations may represent a valid alternative to improve patient compliance and to achieve more efficacious therapeutic outcomes.
全反式维甲酸(ATRA)是包括上皮性皮肤癌和痤疮在内的多种皮肤病的首选治疗药物。然而,ATRA的皮肤副作用,如发红和脱皮,以及其高不稳定性限制了其疗效。为了解决这些缺点并改善ATRA的溶解性,我们通过将其包裹在D-α-生育酚聚乙二醇琥珀酸酯(TPGS)中制备了载ATRA的胶束(ATRA-TPGSs)。首先,为了探索该项目的可行性,进行了基于平衡法的溶解度研究;然后,使用不同量的TPGS通过溶剂浇铸法制备了六种ATRA-TPGS制剂。ATRA-TPGSs显示出小尺寸(1l-2nm)、低多分散性、略微负的zeta电位,并通过化学计量学辅助傅里叶变换红外光谱(FTIR)研究证实具有良好的包封效率。还研究了ATRA-TPGS的稳定性以选择最稳定的制剂。使用卡波姆980作为胶凝剂,获得了载ATRA-TPGS的凝胶并分析了其流变学特性。通过Franz细胞进行了ATRA-TPGSs的体外释放研究,结果表明24小时后的渗透率为22±4μcm。ATRA-TPGSs对黑色素瘤细胞显示出增强的细胞毒性作用,表明这些制剂可能是提高患者依从性并实现更有效治疗效果的有效替代方案。